Illumina, Inc. (ILMN)
January 25, 2012 7:00 am ET
Daniel O'Day - Chief Executive Officer of Roche Molecular Diagnostics and President of Roche Molecular Diagnostics
Severin Schwan - Chief Executive officer
Alan Hippe - Chief Financial and IT Officer
Vincent Meunier - Exane BNP Paribas, Research Division
Gbola Amusa - UBS Investment Bank, Research Division
Keyur Parekh - Goldman Sachs Group Inc., Research Division
Luisa Hector - Crédit Suisse AG, Research Division
Sachin Jain - BofA Merrill Lynch, Research Division
Alexandra Hauber - JP Morgan Chase & Co, Research Division
Quintin J. Lai - Robert W. Baird & Co. Incorporated, Research Division
Michael Leacock - RBS Research
William R. Quirk - Piper Jaffray Companies, Research Division
Good morning or good afternoon. Welcome to the Roche conference call regarding the Illumina transaction. I'm Dino, the Chorus Call operator. [Operator Instructions] And the conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Severin Schwan, CEO. Please go ahead, sir.
Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O'Day, Chief Operating Officer of Roche Diagnostics.
Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today's success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.